Beyond AAV: Unlocking the Potential of Gene Therapy with Novel Parvovirus Vectors

Time: 2:30 pm
day: Conference Day Two


  • New recombinant non-AAV parvovirus vectors designed to overcome many of the challenges associated with AAV vectors
  • CBN-1100 is a vector derived from a natural parvovirus species featuring higher cargo capacity compared to AAV, potency in diverse cell types, a compelling liver de-targeted distribution profile, high manufacturability and scalability, and minimal human seroprevalence
  • The pharmacological attributes of CBN-1100, including in nonhuman primates, demonstrate that viral vectors powered by natural non-AAV parvovirus capsids offer a path forward for numerous targets and indications that are undruggable using current gene therapy technology